身体质量指数和心房动之间的调解者:孟德尔的随机化研究
Ziting Gao1, Hongye Wei1, Jun Xiao2,3
1Department of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, Fuzhou, China.
Frontiers in nutrition
|June 6, 2024
概括
肥胖增加了心房动 (AF) 的风险,而丁则调解了这一联系. 这种风险进一步受到睡眠呼吸暂停和心脏病等疾病的影响,突出了关键机制.
科学领域:
- 心血管遗传学 心血管遗传学
- 代谢性疾病研究研究
- 流行病学 流行病学
背景情况:
- 肥胖是心房动 (AF) 的已知的危险因素,但确切的机制尚不清楚.
- 了解身体质量指数 (BMI) 和AF之间的联系对于开发有针对性的干预措施至关重要.
- 现有的研究指出了潜在的调解因素,但需要进行全面的分析.
研究的目的:
- 研究各种生物标志物和并发症在人体质量指数 (BMI) 和心房动 (AF) 之间的因果关系中的潜在调解作用.
- 阐明高BMI有助于AF发展的特定途径.
- 确定可以针对治疗策略的关键调解者.
主要方法:
- 使用公开可用的全基因组关联研究总结统计数据,采用双样本的门德尔随机化 (MR) 分析.
- 单变量MR确定了潜在的媒介,其次是多变量MR,以评估循环生物标记物,代谢标记物和并发症的媒介作用.
- 该研究分析了BMI-AF关联的减弱,经过对特定介质进行调整后.
主要成果:
- 证实了较高的BMI和增加的AF风险之间的显著因果关系 (OR=1.41).
- 莱普被确定为一个显著的调解剂,将BMI-AF关联降低了48.78% (OR=1.21).
- 进一步调整睡眠呼吸暂停,冠状动脉疾病和静脉血压等并发症,以及叶黄素,大大减弱了相关性,表明存在实质性的调解 (73-88%).
结论:
- 莱普在调解肥胖和心房动之间的因果关系方面发挥着至关重要的作用.
- 丁的调解作用在患有睡眠呼吸暂停,冠状动脉疾病和高血压等并发疾病的个体中尤为明显.
- 这些发现提供了对肥胖对AF风险影响的复杂机制的宝贵见解,表明了潜在的治疗点.
更多相关视频
28:13Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.4K
08:10Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
1.7K
相关概念视频
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
